Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450 g/BO21976)

被引：16

作者：

Hurvitz, S. ^{[1
]}

Dirix, L. ^{[2
]}

Kocsis, J. ^{[3
]}

Gianni, L. ^{[4
]}

Lu, J. ^{[5
]}

Vinholes, J. ^{[6
]}

Song, C. ^{[7
]}

Tong, B. ^{[8
]}

Chu, Y. W. ^{[7
]}

Perez, E. A. ^{[9
]}

机构：

[1] Univ Calif Los Angeles, Sch Med, Internal Med Div Heme Onc, Los Angeles, CA USA

[2] Sint Augustinus Hosp, Dept Med Oncol, Antwerp, Belgium

[3] Semmelweis Univ, Dept Internal Med 3, Budapest, Hungary

[4] Hosp San Raffaele, Dept Med Oncol, I-20132 Milan, Italy

[5] SUNY Stony Brook, Div Hematol & Oncol, Stony Brook, NY 11794 USA

[6] Clin Oncol, Porto Alegre, RS, Brazil

[7] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA

[8] Genentech Inc, Prod Dev Biostat, San Francisco, CA 94080 USA

[9] Mayo Clin, Div Hematol Oncol, Jacksonville, FL USA

来源：

关键词：

D O I：

10.1016/S0959-8049(11)71443-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：S330 / S330

页数：1